Amalgamated Bank Biocryst Pharmaceuticals Inc Transaction History

Amalgamated Bank

$13.6 Billion
Q3 2025

A detailed history of Amalgamated Bank transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Amalgamated Bank holds 7,155 shares of BCRX stock, worth $49,369. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,155

Previous 7,155 -0.0%

Holding current value

$49,369

Previous $64,000 15.63%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 25, 2025	BUY	$7.06 - $9.39 $3,120 - $4,150	442 Added 6.58%	7,155 $54,000
Q2 2024 Aug 12, 2024	BUY	$4.13 - $6.79 $1,511 - $2,485	366 Added 5.77%	6,713 $41,000
Q1 2024 Apr 23, 2024	SELL	$4.89 - $7.65 $87,579 - $137,011	-17,910 Reduced 73.83%	6,347 $32,000
Q4 2023 Feb 06, 2024	SELL	$4.98 - $6.77 $9,407 - $12,788	-1,889 Reduced 7.22%	24,257 $145,000
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $13,404 - $16,968	1,926 Added 7.95%	26,146 $184,000
Q1 2023 May 02, 2023	SELL	$7.94 - $11.84 $29,227 - $43,583	-3,681 Reduced 13.19%	24,220 $202,000
Q3 2022 Nov 09, 2022	BUY	$10.79 - $14.81 $3,539 - $4,857	328 Added 1.19%	27,901 $352,000
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $35,355 - $80,120	4,481 Added 19.4%	27,573 $292,000
Q1 2022 Jun 30, 2022	SELL	$11.56 - $19.76 $11,294 - $19,305	-977 Reduced 4.06%	23,092 $375,000
Q4 2021 Feb 15, 2022	SELL	$11.18 - $15.46 $1,039 - $1,437	-93 Reduced 0.38%	24,069 $333,000
Q3 2021 Oct 29, 2021	SELL	$14.21 - $17.65 $23,972 - $29,775	-1,687 Reduced 6.53%	24,162 $347,000
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $26,685 - $48,427	2,809 Added 12.19%	25,849 $409,000
Q1 2021 May 13, 2021	SELL	$7.37 - $13.61 $10,126 - $18,700	-1,374 Reduced 5.63%	23,040 $234,000
Q4 2020 Feb 12, 2021	BUY	$3.37 - $8.61 $465 - $1,188	138 Added 0.57%	24,414 $181,000
Q3 2020 Oct 30, 2020	BUY	$3.43 - $5.53 $7,642 - $12,320	2,228 Added 10.11%	24,276 $83,000
Q2 2020 Aug 10, 2020	SELL	$1.9 - $5.61 $2,831 - $8,358	-1,490 Reduced 6.33%	22,048 $105,000
Q1 2020 May 13, 2020	BUY	$1.6 - $4.11 $5,595 - $14,372	3,497 Added 17.45%	23,538 $47,000
Q4 2019 Feb 13, 2020	BUY	$1.59 - $3.45 $1,055 - $2,290	664 Added 3.43%	20,041 $69,000
Q3 2019 Nov 13, 2019	SELL	$2.5 - $3.73 $350 - $522	-140 Reduced 0.72%	19,377 $56,000
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $10,909 - $34,303	3,749 Added 23.78%	19,517 $74,000
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $4,398 - $5,793	596 Added 3.93%	15,768 $128,000
Q4 2018 Feb 15, 2019	BUY	$6.51 - $9.6 $98,769 - $145,651	15,172 New	15,172 $122,000
Q3 2018 Nov 14, 2018	SELL	$5.52 - $7.99 $81,889 - $118,531	-14,835 Closed	0 $0
Q2 2018 Jul 18, 2018	BUY	$4.6 - $6.52 $7,571 - $10,731	1,646 Added 12.48%	14,835 $85,000
Q1 2018 May 22, 2018	SELL	$4.35 - $5.82 $743 - $995	-171 Reduced 1.28%	13,189 $63,000
Q4 2017 Feb 13, 2018	BUY	$4.16 - $5.33 $13,191 - $16,901	3,171 Added 31.12%	13,360 $66,000
Q3 2017 Nov 09, 2017	BUY	$4.1 - $5.97 $41,774 - $60,828	10,189	10,189 $53,000

Others Institutions Holding BCRX

# of Institutions

311

Shares Held

202M

Call Options Held

765K

Put Options Held

511K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.28B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Biocryst Pharmaceuticals Inc Transaction History